Cyclacel Pharmaceuticals Net Worth
Cyclacel Pharmaceuticals Net Worth Breakdown | CYCC |
Cyclacel Pharmaceuticals Net Worth Analysis
Cyclacel Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cyclacel Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cyclacel Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cyclacel Pharmaceuticals' net worth analysis. One common approach is to calculate Cyclacel Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cyclacel Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cyclacel Pharmaceuticals' net worth. This approach calculates the present value of Cyclacel Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cyclacel Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cyclacel Pharmaceuticals' net worth. This involves comparing Cyclacel Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cyclacel Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Cyclacel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclacel Pharmaceuticals' net worth research are outlined below:
| Cyclacel Pharmaceuticals had very high historical volatility over the last 90 days | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from zacks.com: All You Need to Know About Cyclacel Pharmaceuticals Rating Upgrade to Buy |
Cyclacel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cyclacel Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclacel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cyclacel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cyclacel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclacel Pharmaceuticals backward and forwards among themselves. Cyclacel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cyclacel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-03-31 | 3.0 | State Street Corporation | 2023-12-31 | 0.0 | Schonfeld Strategic Advisors Llc | 2024-03-31 | 0.0 | Altium Capital Management, Lp | 2024-03-31 | 0.0 | Northern Trust Corp | 2023-12-31 | 0.0 | Kpp Advisory Services Llc | 2023-12-31 | 0.0 | Millennium Management Llc | 2023-12-31 | 0.0 | Raymond James Finl Svs Advisors, Inc. | 2023-12-31 | 0.0 | Vanguard Group Inc | 2023-12-31 | 0.0 | Renaissance Technologies Corp | 2024-03-31 | 20.8 K | Point72 Asset Management, L.p. | 2024-03-31 | 15.3 K |
Follow Cyclacel Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.93 M.Market Cap |
|
Project Cyclacel Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.56) | (2.43) | |
| Return On Capital Employed | (47.05) | (44.70) | |
| Return On Assets | (2.56) | (2.43) | |
| Return On Equity | (37.16) | (35.30) |
When accessing Cyclacel Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cyclacel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclacel Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Cyclacel Pharmaceuticals' official financial statements typically reflect Cyclacel Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cyclacel Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by Cyclacel accountants, it’s essential to understand Cyclacel Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Cyclacel Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuticals' management manipulating its earnings.
Evaluate Cyclacel Pharmaceuticals' management efficiency
Cyclacel Pharmaceuticals has return on total asset (ROA) of (0.996) % which means that it has lost $0.996 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9602) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.43. The current year's Return On Capital Employed is expected to grow to -44.7. At present, Cyclacel Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.9 M, whereas Total Assets are forecasted to decline to about 8.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.71 | 0.75 | |
| Tangible Book Value Per Share | 0.71 | 0.75 | |
| Enterprise Value Over EBITDA | 0.04 | 0.04 | |
| Price Book Value Ratio | 3.74 | 3.93 | |
| Enterprise Value Multiple | 0.04 | 0.04 | |
| Price Fair Value | 3.74 | 3.93 | |
| Enterprise Value | -1.1 M | -1 M |
The analysis of Cyclacel Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Cyclacel Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Cyclacel Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 6.0999 | Revenue 449 K | Revenue Per Share 0.465 | Return On Equity (4.96) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclacel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclacel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclacel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Banham John Michael Middlecott over a week ago Acquisition by Banham John Michael Middlecott of 5200 shares of Cyclacel Pharmaceuticals at 4.7 subject to Rule 16b-3 | ||
Barker Sam L over three weeks ago Acquisition by Barker Sam L of 5200 shares of Cyclacel Pharmaceuticals at 4.7 subject to Rule 16b-3 | ||
Walker Karin L over a month ago Insider Trading | ||
Eastern Capital Ltd over two months ago Insider Trading | ||
Spiro Rombotis over three months ago Purchase by Spiro Rombotis of 6070 shares of Cyclacel Pharmaceuticals | ||
Spiro Rombotis over six months ago Acquisition by Spiro Rombotis of 110000 shares of Cyclacel Pharmaceuticals subject to Rule 16b-3 | ||
Spiro Rombotis over a year ago Acquisition by Spiro Rombotis of 57600 shares of Cyclacel Pharmaceuticals subject to Rule 16b-3 |
Cyclacel Pharmaceuticals Earnings per Share Projection vs Actual
Additional Information and Resources on Investing in Cyclacel Stock
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.02) | Revenue Per Share 0.465 | Return On Assets (1.00) | Return On Equity (4.96) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.